SARS-CoV-2 Mpro-IN-9
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM) [1].
Product Specifications
CAS Number
2754370-99-3
UNSPSC
12352005
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-mpro-in-9.html
Solubility
10 mM in DMSO
Smiles
O=C1N(C2=CC=CC=C2)C(C3=CC=CC=C3)=NC4=C1C(O)=C(O)C(O)=C4
Molecular Formula
C20H14N2O4
Molecular Weight
346.34
References & Citations
[1]Zhang K, et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) . Eur J Med Chem. 2023 Sep 5;257:115487.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K4802003 1.0 µg DNA
Lpcat3 sgRNA CRISPR Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details 